Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

G Zhu, L Pei, H Xia, Q Tang, F Bi - Molecular cancer, 2021 - Springer
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

Liver metastases

DI Tsilimigras, P Brodt, PA Clavien… - Nature reviews Disease …, 2021 - nature.com
Liver metastases are commonly detected in a range of malignancies including colorectal
cancer (CRC), pancreatic cancer, melanoma, lung cancer and breast cancer, although CRC …

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

DM Kurtz, J Soo, L Co Ting Keh, S Alig… - Nature …, 2021 - nature.com
Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …

Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics

P Song, LR Wu, YH Yan, JX Zhang, T Chu… - Nature biomedical …, 2022 - nature.com
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond

L Keller, Y Belloum, H Wikman, K Pantel - British journal of cancer, 2021 - nature.com
Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …

Clinical application and detection techniques of liquid biopsy in gastric cancer

S Ma, M Zhou, Y Xu, X Gu, M Zou, G Abudushalamu… - Molecular Cancer, 2023 - Springer
Gastric cancer (GC) is one of the most common tumors worldwide and the leading cause of
tumor-related mortality. Endoscopy and serological tumor marker testing are currently the …

Circulating tumor DNA and liquid biopsy in oncology

DW Cescon, SV Bratman, SM Chan, LL Siu - Nature cancer, 2020 - nature.com
Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …

[HTML][HTML] The emerging role of cell-free DNA as a molecular marker for cancer management

AJ Bronkhorst, V Ungerer, S Holdenrieder - Biomolecular detection and …, 2019 - Elsevier
An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Liquid biopsies come of age: towards implementation of circulating tumour DNA

JCM Wan, C Massie, J Garcia-Corbacho… - Nature Reviews …, 2017 - nature.com
Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …

Integrating liquid biopsies into the management of cancer

G Siravegna, S Marsoni, S Siena… - Nature reviews Clinical …, 2017 - nature.com
During cancer progression and treatment, multiple subclonal populations of tumour cells
compete with one another, with selective pressures leading to the emergence of …